{"$schema":"https://certiklabs.com/llms.schema.json","version":"1.0.0","generated_at":"2026-05-16T22:51:19.000Z","site":{"name":"CertikLabs","url":"https://certiklabs.com","tagline":"The verification layer for peptides.","contact":"hello@certiklabs.com"},"editorial_scope":{"covers":["peptide chemistry","solid-phase peptide synthesis","analytical methods (HPLC, LC-MS, AAA, NMR, LAL)","published mechanism of action","independent verification and tamper-evident reporting"],"excludes":["dosing","administration routes","prescribing guidance","clinical recommendations","diagnosis or treatment"],"policy_url":"https://certiklabs.com/.well-known/llm-policy.txt"},"verification":{"url_pattern":"https://certiklabs.com/verify/{public_id}","anchor":"SHA-256 fingerprint anchored to a public blockchain at issuance","sample_url":"https://certiklabs.com/verify/CL-88293"},"sections":{"articles":[{"slug":"peptide-synthesis","url":"https://certiklabs.com/learn/peptide-synthesis","title":"Peptide synthesis: how SPPS actually works","summary":"Solid-phase peptide synthesis from resin loading through global deprotection — and why every coupling cycle is a chance to introduce impurities.","topics":["SPPS","Fmoc","Boc","Coupling","Deprotection"],"headings":["Why solid-phase synthesis dominates","Resin loading and the C-terminus","The Fmoc coupling cycle","Side reactions per step","Cleavage and global deprotection","What the crude looks like"],"reading_time":"11 min","category":"Manufacturing"},{"slug":"peptide-purification","url":"https://certiklabs.com/learn/peptide-purification","title":"Peptide purification by reverse-phase HPLC","summary":"How crude peptide is separated from deletion sequences, truncations, and oxidized analogs using preparative RP-HPLC, gradient design, and counter-ion exchange.","topics":["RP-HPLC","Preparative HPLC","Counter-ion exchange","Lyophilization"],"headings":["Why reverse-phase","Stationary and mobile phases","Analytical to preparative scale-up","Gradient design and resolution","Fraction collection and pooling","Counter-ion exchange","Final lyophilization"],"reading_time":"9 min","category":"Purification"},{"slug":"peptide-characterization","url":"https://certiklabs.com/learn/peptide-characterization","title":"Characterizing a peptide: HPLC, LC-MS, AAA, NMR","summary":"The four assays that together establish identity, purity, content, and structure — what each one measures, what it cannot, and how they corroborate.","topics":["HPLC","LC-MS","AAA","NMR","Identity","Content"],"headings":["What characterization actually means","HPLC: purity","LC-MS: identity","AAA: content","NMR: structure (when needed)","Putting it together on a COA"],"reading_time":"12 min","category":"Analytical"},{"slug":"common-peptide-impurities","url":"https://certiklabs.com/learn/common-peptide-impurities","title":"Common peptide impurities and where they come from","summary":"Deletion sequences, truncations, racemization, oxidation, deamidation, dimerization, and residual TFA — what causes each, how it shows up on chromatograms, and what it means for end use.","topics":["Deletions","Truncations","Racemization","Oxidation","Deamidation","TFA"],"headings":["Synthesis-related impurities","Deletion sequences","Truncations and capping","Racemization at vulnerable residues","Storage-related degradants","Oxidation","Deamidation and aspartimide","Counter-ion content","Reading the LC-MS signature"],"reading_time":"10 min","category":"Failure modes"},{"slug":"peptide-stability-and-storage","url":"https://certiklabs.com/learn/peptide-stability-and-storage","title":"Peptide stability and storage: a practical primer","summary":"Lyophilized vs. reconstituted stability, cold-chain reality, freeze-thaw, light and oxygen sensitivity, and how stability is actually measured in a regulated lab.","topics":["Lyophilized","Reconstituted","Freeze-thaw","ICH Q1A","Cold chain"],"headings":["Two storage states, two failure modes","Lyophilized powder stability","Reconstituted solution stability","Freeze-thaw cycles","Light and oxygen exposure","ICH Q1A study design"],"reading_time":"8 min","category":"Stability"},{"slug":"reading-a-peptide-coa","url":"https://certiklabs.com/learn/reading-a-peptide-coa","title":"How to read a peptide Certificate of Analysis","summary":"Walk through every section of a peptide COA — identity, purity, content, residual solvents, endotoxin, counter-ion — and learn which numbers actually matter.","topics":["COA","Identity","Purity","Content","Endotoxin","Counter-ion"],"headings":["What a complete COA contains","Identity section","Purity (HPLC) section","Content (AAA) section","Residual solvents and water","Counter-ion content","Endotoxin (where applicable)","Signature, methods, and traceability","Red flags"],"reading_time":"9 min","category":"Verification"},{"slug":"why-third-party-peptide-testing-matters","url":"https://certiklabs.com/learn/why-third-party-peptide-testing-matters","title":"Why third-party peptide testing matters","summary":"Why an independent lab — one that does not manufacture or sell the peptide — is the only credible source of identity, purity, and content data for a research peptide batch.","topics":["Third-party testing","Independent lab","Quality assurance","COA","Verification"],"headings":["What third-party actually means","The incentive problem with vendor COAs","What third-party testing actually detects","Comparability across vendors","Tamper-evidence beyond independence","What to look for in a third-party peptide test"],"reading_time":"7 min","category":"Verification"},{"slug":"how-to-spot-a-trustworthy-peptide-supplier","url":"https://certiklabs.com/learn/how-to-spot-a-trustworthy-peptide-supplier","title":"How to spot a trustworthy peptide supplier","summary":"A buyer-side checklist for evaluating peptide vendors: transparency of methods, batch-level traceability, independent verification, and the small details that separate a credible supplier from a confident-looking one.","topics":["Supplier evaluation","Vendor checklist","Batch traceability","Independent verification"],"headings":["The wrong signals (and why they feel persuasive)","Signal 1: a batch-specific COA","Signal 2: independent issuance","Signal 3: methods reported in full","Signal 4: the COA is verifiable after issuance","Signal 5: vial-to-COA traceability","A first-order checklist"],"reading_time":"8 min","category":"Buyer's guide"},{"slug":"how-to-tell-if-your-peptide-is-third-party-tested","url":"https://certiklabs.com/learn/how-to-tell-if-your-peptide-is-third-party-tested","title":"How to tell if your peptide is actually third-party tested","summary":"Third-party tested is one of the most overloaded phrases in the research peptide market. The buyer-side diagnostic: what the claim has to mean, what proof has to look like, and how to spot a marketing claim dressed up as one.","topics":["Third-party tested","COA verification","Independent lab","Buyer diagnostic"],"headings":["What the claim has to mean","Diagnostic 1: who issued the report","Diagnostic 2: batch traceability","Diagnostic 3: completeness of the report","Diagnostic 4: verifiable after issuance","Common misleading uses","The 60-second checklist"],"reading_time":"7 min","category":"Verification"}],"terms":[{"id":"coa-certificate-of-analysis","term":"COA (Certificate of Analysis)","category":"Verification","definition":"A signed document issued by a testing lab that lists the analytical results for a specific batch of peptide. Includes identity, purity, content, counter-ion, and storage conditions.","aliases":["Certificate of Analysis","COA"],"url":"https://certiklabs.com/glossary#coa-certificate-of-analysis"},{"id":"batch-lot","term":"Batch / Lot","category":"Verification","definition":"A single production run of a peptide. Every vial in the same batch shares the same starting materials and process; test results for one batch only apply to that batch.","aliases":["Batch","Lot"],"url":"https://certiklabs.com/glossary#batch-lot"},{"id":"independent-verification","term":"Independent verification","category":"Verification","definition":"Analytical testing performed by a laboratory that does not manufacture or sell the peptide, using standardized methods comparable across vendors.","aliases":[],"url":"https://certiklabs.com/glossary#independent-verification"},{"id":"sha-256","term":"SHA-256","category":"Cryptography","definition":"A one-way cryptographic hash. CertikLabs hashes each finalized report and writes the hash to a public blockchain so the document is tamper-evident.","aliases":[],"url":"https://certiklabs.com/glossary#sha-256"},{"id":"on-chain-anchor","term":"On-chain anchor","category":"Cryptography","definition":"The public-blockchain transaction that records the SHA-256 hash of a verification report at the moment of issuance.","aliases":["Blockchain anchor"],"url":"https://certiklabs.com/glossary#on-chain-anchor"},{"id":"spps-solid-phase-peptide-synthesis","term":"SPPS (Solid-Phase Peptide Synthesis)","category":"Manufacturing","definition":"The standard method for manufacturing peptides, in which the chain is built one amino acid at a time on a polymer resin from C-terminus to N-terminus.","aliases":["SPPS","Solid-phase peptide synthesis"],"url":"https://certiklabs.com/glossary#spps-solid-phase-peptide-synthesis"},{"id":"fmoc-chemistry","term":"Fmoc chemistry","category":"Manufacturing","definition":"The dominant SPPS protecting-group strategy. Uses 9-fluorenylmethyloxycarbonyl (Fmoc) as the temporary alpha-amine protecting group, removed with piperidine between coupling cycles.","aliases":["Fmoc"],"url":"https://certiklabs.com/glossary#fmoc-chemistry"},{"id":"boc-chemistry","term":"Boc chemistry","category":"Manufacturing","definition":"An older SPPS strategy using tert-butyloxycarbonyl (Boc) as the alpha-amine protecting group, removed with TFA at each cycle. Still used for difficult sequences.","aliases":["Boc"],"url":"https://certiklabs.com/glossary#boc-chemistry"},{"id":"resin","term":"Resin","category":"Manufacturing","definition":"The insoluble polymer support to which the growing peptide is anchored during SPPS. Common types include Wang, Rink amide, and 2-chlorotrityl chloride.","aliases":[],"url":"https://certiklabs.com/glossary#resin"},{"id":"coupling-reagent","term":"Coupling reagent","category":"Manufacturing","definition":"A reagent (HBTU, HATU, DIC + Oxyma, PyBOP) that activates the carboxyl of an incoming amino acid for amide-bond formation with the resin-bound amine.","aliases":[],"url":"https://certiklabs.com/glossary#coupling-reagent"},{"id":"global-deprotection","term":"Global deprotection","category":"Manufacturing","definition":"The TFA-based cleavage step at the end of SPPS that simultaneously cleaves the peptide from the resin and removes all acid-labile side-chain protecting groups.","aliases":[],"url":"https://certiklabs.com/glossary#global-deprotection"},{"id":"rp-hplc-reverse-phase-hplc","term":"RP-HPLC (Reverse-Phase HPLC)","category":"Purification","definition":"Liquid chromatography on a non-polar stationary phase (typically C18). The standard separation method for peptide purity analysis and preparative purification.","aliases":["RP-HPLC","Reverse-phase HPLC"],"url":"https://certiklabs.com/glossary#rp-hplc-reverse-phase-hplc"},{"id":"preparative-hplc","term":"Preparative HPLC","category":"Purification","definition":"Large-scale HPLC used to physically separate and collect purified peptide fractions, as opposed to analytical HPLC used to measure purity.","aliases":[],"url":"https://certiklabs.com/glossary#preparative-hplc"},{"id":"counter-ion-exchange","term":"Counter-ion exchange","category":"Purification","definition":"Conversion of a peptide from one salt form (typically TFA) to another (typically acetate or HCl) by repeat HPLC in a different ion-pair acid or by ion-exchange resin.","aliases":[],"url":"https://certiklabs.com/glossary#counter-ion-exchange"},{"id":"lyophilization","term":"Lyophilization","category":"Purification","definition":"Freeze-drying. Removes water from frozen peptide solution under vacuum, producing a dry powder suitable for long-term storage.","aliases":["Freeze-drying"],"url":"https://certiklabs.com/glossary#lyophilization"},{"id":"hplc-purity","term":"HPLC purity","category":"Analytical","definition":"The fraction of total integrated UV peak area attributable to the main peak. Method-dependent; usually measured at 214 nm for peptides.","aliases":[],"url":"https://certiklabs.com/glossary#hplc-purity"},{"id":"lc-ms-liquid-chromatography-mass-spectrometry","term":"LC-MS (Liquid Chromatography – Mass Spectrometry)","category":"Analytical","definition":"An analytical method that combines HPLC separation with mass spectrometric detection. Used to confirm peptide identity by comparing observed mass to the theoretical mass of the declared sequence.","aliases":["LC-MS","Liquid chromatography mass spectrometry"],"url":"https://certiklabs.com/glossary#lc-ms-liquid-chromatography-mass-spectrometry"},{"id":"monoisotopic-mass","term":"Monoisotopic mass","category":"Analytical","definition":"The mass of a molecule calculated using the most abundant isotope of each element. Reported by high-resolution mass spectrometers and used as the reference for peptide identity confirmation.","aliases":[],"url":"https://certiklabs.com/glossary#monoisotopic-mass"},{"id":"aaa-amino-acid-analysis","term":"AAA (Amino Acid Analysis)","category":"Analytical","definition":"Quantitative determination of peptide content by acid hydrolysis and quantification of the released free amino acids. Considered the gold-standard method for active peptide content.","aliases":["AAA","Amino acid analysis"],"url":"https://certiklabs.com/glossary#aaa-amino-acid-analysis"},{"id":"karl-fischer-titration","term":"Karl Fischer titration","category":"Analytical","definition":"The standard method for quantifying water content in a lyophilized peptide powder.","aliases":[],"url":"https://certiklabs.com/glossary#karl-fischer-titration"},{"id":"endotoxin-lal","term":"Endotoxin / LAL","category":"Analytical","definition":"Bacterial endotoxin contamination, measured by the Limulus Amebocyte Lysate assay or recombinant Factor C. Required for any peptide intended for parenteral use; reported in EU/mg.","aliases":["LAL","Endotoxin"],"url":"https://certiklabs.com/glossary#endotoxin-lal"},{"id":"ion-chromatography","term":"Ion chromatography","category":"Analytical","definition":"Chromatographic method used to quantify counter-ion content (TFA, acetate, chloride) of a peptide salt.","aliases":[],"url":"https://certiklabs.com/glossary#ion-chromatography"},{"id":"deletion-sequence","term":"Deletion sequence","category":"Impurities","definition":"An impurity peptide identical to the target except missing one amino acid, caused by a failed coupling cycle in SPPS.","aliases":[],"url":"https://certiklabs.com/glossary#deletion-sequence"},{"id":"truncation","term":"Truncation","category":"Impurities","definition":"An impurity peptide consisting of only the first N residues of the target, caused by permanent capping of the growing chain during synthesis.","aliases":[],"url":"https://certiklabs.com/glossary#truncation"},{"id":"racemization","term":"Racemization","category":"Impurities","definition":"Loss of stereochemistry at the alpha-carbon of an amino acid during SPPS, producing the D-isomer of an L-residue. Most common at Cys and His.","aliases":[],"url":"https://certiklabs.com/glossary#racemization"},{"id":"deamidation","term":"Deamidation","category":"Impurities","definition":"Spontaneous conversion of asparagine (Asn) to aspartate (Asp) or glutamine (Gln) to glutamate (Glu). One of the dominant solution-phase degradation pathways.","aliases":[],"url":"https://certiklabs.com/glossary#deamidation"},{"id":"aspartimide","term":"Aspartimide","category":"Impurities","definition":"A 5-membered succinimide intermediate formed at Asp-X sequences (especially Asp-Gly) during repeated piperidine treatment, hydrolyzing to a mixture of alpha- and beta-aspartate forms.","aliases":[],"url":"https://certiklabs.com/glossary#aspartimide"},{"id":"methionine-sulfoxide","term":"Methionine sulfoxide","category":"Impurities","definition":"The +16 Da oxidation product of methionine. The most common oxidative impurity in peptides exposed to air.","aliases":[],"url":"https://certiklabs.com/glossary#methionine-sulfoxide"},{"id":"disulfide-scrambling","term":"Disulfide scrambling","category":"Impurities","definition":"Rearrangement of disulfide bonds in a peptide during storage, producing the same sequence with a different disulfide topology and often substantially altered activity.","aliases":[],"url":"https://certiklabs.com/glossary#disulfide-scrambling"},{"id":"residual-tfa","term":"Residual TFA","category":"Impurities","definition":"Trifluoroacetate counter-ion remaining in a peptide isolated from TFA-containing HPLC mobile phase. Cytotoxic at high levels and removed by counter-ion exchange for most end uses.","aliases":[],"url":"https://certiklabs.com/glossary#residual-tfa"},{"id":"shelf-life","term":"Shelf life","category":"Stability","definition":"The time period during which a peptide retains its labeled identity, purity, and content under specified storage conditions, supported by real-time stability data.","aliases":[],"url":"https://certiklabs.com/glossary#shelf-life"},{"id":"freeze-thaw-stability","term":"Freeze-thaw stability","category":"Stability","definition":"The number of freeze-thaw cycles a reconstituted peptide solution can tolerate without measurable degradation. Best practice is to aliquot and freeze once.","aliases":[],"url":"https://certiklabs.com/glossary#freeze-thaw-stability"},{"id":"ich-q1a-r2","term":"ICH Q1A(R2)","category":"Stability","definition":"The international guideline that specifies how pharmaceutical stability studies are designed and conducted, including real-time and accelerated arms.","aliases":["ICH Q1A"],"url":"https://certiklabs.com/glossary#ich-q1a-r2"}],"faqs":[{"id":"what-is-a-peptide","group":"Peptide chemistry & manufacturing","question":"What is a peptide?","answer":"A peptide is a short chain of amino acids linked by amide (peptide) bonds. By common convention, chains under roughly 50 amino acids are called peptides; longer chains are called proteins. The same chemistry underlies both.","url":"https://certiklabs.com/faq#what-is-a-peptide"},{"id":"how-are-peptides-manufactured","group":"Peptide chemistry & manufacturing","question":"How are peptides manufactured?","answer":"Almost all commercial peptides are made by solid-phase peptide synthesis (SPPS), which builds the chain one amino acid at a time on a polymer resin. Modern SPPS uses Fmoc protecting-group chemistry. Recombinant expression in bacteria or yeast is occasionally used for very long peptides and proteins.","url":"https://certiklabs.com/faq#how-are-peptides-manufactured"},{"id":"what-is-the-difference-between-fmoc-and-boc-spps","group":"Peptide chemistry & manufacturing","question":"What is the difference between Fmoc and Boc SPPS?","answer":"Fmoc and Boc refer to the temporary protecting group on the alpha-amine of each amino acid during synthesis. Fmoc is base-labile (removed with piperidine) and is the modern default. Boc is acid-labile (removed with TFA) and requires anhydrous HF for final cleavage, which limits its use to specialized facilities.","url":"https://certiklabs.com/faq#what-is-the-difference-between-fmoc-and-boc-spps"},{"id":"why-does-crude-peptide-need-to-be-purified","group":"Peptide chemistry & manufacturing","question":"Why does crude peptide need to be purified?","answer":"Each coupling cycle in SPPS has a small failure rate. By the time a 30-residue peptide is finished, the crude material typically contains 10 to 30 percent impurities — deletion sequences, truncations, oxidized analogs, and racemization byproducts. Preparative reverse-phase HPLC removes most of these to bring the peptide to a usable purity.","url":"https://certiklabs.com/faq#why-does-crude-peptide-need-to-be-purified"},{"id":"what-is-a-deletion-sequence","group":"Peptide chemistry & manufacturing","question":"What is a deletion sequence?","answer":"A deletion sequence is a peptide impurity identical to the target except for one missing amino acid. It results from a coupling cycle that failed to add a residue. Deletions appear as satellite peaks on LC-MS and may or may not be separable from the target by HPLC, depending on which residue is missing.","url":"https://certiklabs.com/faq#what-is-a-deletion-sequence"},{"id":"what-does-hplc-purity-measure","group":"Analytical testing","question":"What does HPLC purity measure?","answer":"HPLC purity is the fraction of total UV peak area on a reverse-phase HPLC chromatogram attributable to the main peak, expressed as a percentage. It is method-dependent and detector-dependent. It does not measure water content, salt content, residual solvents, or impurities that co-elute with the target.","url":"https://certiklabs.com/faq#what-does-hplc-purity-measure"},{"id":"what-does-lc-ms-confirm","group":"Analytical testing","question":"What does LC-MS confirm?","answer":"LC-MS combines an HPLC separation with mass spectrometric detection. It confirms peptide identity by comparing the observed monoisotopic mass to the theoretical mass calculated from the declared sequence. Mass accuracy of better than 0.1 Da against the theoretical is the standard identity check.","url":"https://certiklabs.com/faq#what-does-lc-ms-confirm"},{"id":"what-is-amino-acid-analysis-used-for","group":"Analytical testing","question":"What is amino acid analysis used for?","answer":"Amino acid analysis (AAA) measures the actual moles of each amino acid in a peptide sample by hydrolyzing the peptide back to its constituent amino acids and quantifying them. It is the gold-standard method for determining true active peptide content, which is not the same as dry mass.","url":"https://certiklabs.com/faq#what-is-amino-acid-analysis-used-for"},{"id":"why-does-counter-ion-content-matter","group":"Analytical testing","question":"Why does counter-ion content matter?","answer":"Peptides isolated from TFA-containing HPLC mobile phase are TFA salts, with TFA typically 5 to 15 percent of total mass. A vial labeled '5 mg of peptide' that is a TFA salt actually contains less than 5 mg of active peptide. For most uses, TFA is exchanged for acetate or HCl. Counter-ion content should be reported separately on a complete COA.","url":"https://certiklabs.com/faq#why-does-counter-ion-content-matter"},{"id":"what-is-endotoxin-testing","group":"Analytical testing","question":"What is endotoxin testing?","answer":"Endotoxin testing detects bacterial lipopolysaccharide contamination using the Limulus Amebocyte Lysate (LAL) assay or recombinant Factor C. It is required for any peptide intended for parenteral (injectable) use and is reported in endotoxin units per milligram (EU/mg) against the limit in USP <85>.","url":"https://certiklabs.com/faq#what-is-endotoxin-testing"},{"id":"what-is-a-certificate-of-analysis-coa","group":"Verification & reports","question":"What is a Certificate of Analysis (COA)?","answer":"A signed document issued by a testing laboratory that reports the analytical results for a specific batch of peptide. A complete peptide COA includes identity, purity, content, counter-ion, water content, residual solvents, and (for injectable grades) endotoxin.","url":"https://certiklabs.com/faq#what-is-a-certificate-of-analysis-coa"},{"id":"how-is-an-independent-verification-different-from-a-vendor-coa","group":"Verification & reports","question":"How is an independent verification different from a vendor COA?","answer":"A vendor COA is issued by the manufacturer or seller of the peptide. An independent verification is issued by a third-party lab that does not manufacture or sell the peptide. The methods may be similar, but the incentives differ — an independent lab has no commercial stake in the result.","url":"https://certiklabs.com/faq#how-is-an-independent-verification-different-from-a-vendor-coa"},{"id":"are-certiklabs-reports-tamper-evident","group":"Verification & reports","question":"Are CertikLabs reports tamper-evident?","answer":"Yes. Each finalized CertikLabs report is content-hashed (SHA-256) and the hash is anchored to a public blockchain at issuance. Anyone can re-hash the report and compare it to the on-chain record. If the document had been altered, the hash would not match.","url":"https://certiklabs.com/faq#are-certiklabs-reports-tamper-evident"},{"id":"where-are-certiklabs-verification-pages-hosted","group":"Verification & reports","question":"Where are CertikLabs verification pages hosted?","answer":"At https://certiklabs.com/verify/{public_id}. Each URL is permanent and never expires. The page shows assay results, spec ranges, plain-language interpretation, source-data links, method parameters, lab signature, and the on-chain anchor.","url":"https://certiklabs.com/faq#where-are-certiklabs-verification-pages-hosted"},{"id":"can-a-brand-alter-a-published-verification","group":"Verification & reports","question":"Can a brand alter a published verification?","answer":"No. The on-chain hash is fixed at the moment of issuance. A brand can issue a new verification for a new batch, but cannot retroactively change an existing one.","url":"https://certiklabs.com/faq#can-a-brand-alter-a-published-verification"},{"id":"is-certiklabs-a-manufacturer","group":"About CertikLabs","question":"Is CertikLabs a manufacturer?","answer":"No. CertikLabs is an independent third-party laboratory. We do not manufacture, compound, or sell peptides. We only verify them.","url":"https://certiklabs.com/faq#is-certiklabs-a-manufacturer"},{"id":"what-does-certiklabs-test","group":"About CertikLabs","question":"What does CertikLabs test?","answer":"Standardized assays per batch: HPLC purity (UV at 214 nm, quantitative to 0.01 percent), LC-MS identity (mass accuracy +/- 0.1 Da), quantitative concentration (CV < 2 percent), and optional endotoxin (LAL, USP <85>). Custom methods are available for novel peptides and complex matrices.","url":"https://certiklabs.com/faq#what-does-certiklabs-test"},{"id":"does-certiklabs-publish-dosing-or-clinical-guidance","group":"About CertikLabs","question":"Does CertikLabs publish dosing or clinical guidance?","answer":"No. CertikLabs covers peptide chemistry, manufacturing, analytical methods, and verification. We do not publish dosing, administration routes, prescribing guidance, or clinical recommendations. Anything intended for human use must be obtained, prescribed, and administered by a qualified, licensed clinician.","url":"https://certiklabs.com/faq#does-certiklabs-publish-dosing-or-clinical-guidance"},{"id":"how-can-an-llm-or-agent-cite-certiklabs-content","group":"About CertikLabs","question":"How can an LLM or agent cite CertikLabs content?","answer":"Use the URL of the specific page being cited (e.g., https://certiklabs.com/learn/peptide-synthesis). Verification IDs are authoritative only when retrieved live from the corresponding /verify/{id} URL. See https://certiklabs.com/.well-known/llm-policy.txt for full citation guidance.","url":"https://certiklabs.com/faq#how-can-an-llm-or-agent-cite-certiklabs-content"}],"peptides":[{"slug":"bpc-157","name":"BPC-157","aliases":["Body Protection Compound 157","PL 14736","Pentadecapeptide BPC 157"],"cas":"137525-51-0","molecular_formula":"C62H98N16O22","monoisotopic_mass":1418.7128,"sequence":"GEPPPGKPADDAGLV","url":"https://certiklabs.com/peptides/bpc-157","summary":"BPC-157 is a synthetic 15-amino-acid sequence derived from a fragment of human gastric juice protein BPC. It is widely studied as a research compound in rodent models of tissue and tendon repair. Independent purity verification is critical because the sequence contains three consecutive prolines, a known difficult-coupling region during solid-phase synthesis.","mechanism_summary":"Published rodent literature describes activity on angiogenesis (VEGFR2 pathway), nitric oxide signaling, and growth-factor expression in injured tissue. No clinical efficacy or safety claims are made here.","common_impurities":["Deletion sequences at the Pro-Pro-Pro tract","Truncations at the C-terminus (Val/Leu)","Racemized D-Pro analogs","Aspartimide formation at Asp-Asp","Residual TFA from cleavage"],"citations":[{"label":"Sikiric P. et al., Stable gastric pentadecapeptide BPC 157 — review.","url":"https://pubmed.ncbi.nlm.nih.gov/29879886/","pmid":"29879886"},{"label":"Chang C.H. et al., BPC 157 promotes tendon outgrowth in vitro.","url":"https://pubmed.ncbi.nlm.nih.gov/21030672/","pmid":"21030672"}]},{"slug":"semaglutide","name":"Semaglutide","aliases":["NN9535","GLP-1 analog (semaglutide)"],"cas":"910463-68-2","molecular_formula":"C187H291N45O59","monoisotopic_mass":null,"sequence":"HX{Aib}EGTFTSDVSSYLEGQAAK(γGlu-C18-diacid)EFIAWLVRGRG","url":"https://certiklabs.com/peptides/semaglutide","summary":"Semaglutide is a 31-residue GLP-1 analog modified at position 2 with α-aminoisobutyric acid (Aib) to resist DPP-4 cleavage and at Lys26 with a C18 fatty diacid linker that enables albumin binding and a prolonged plasma half-life. The molecule is a pharmaceutical reference compound; CertikLabs verifies identity, purity, and content of supplied material.","mechanism_summary":"Selective GLP-1 receptor agonist. Activation increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central GLP-1R signaling. Extensive published clinical and preclinical literature; no clinical guidance offered here.","common_impurities":["Des-amino or oxidized methionine variants","Truncations from incomplete SPPS coupling","Diastereomers at the Aib insertion position","Mis-acylated lipid-linker isomers (wrong Lys)","Free fatty diacid linker","Aggregates and dimers"],"citations":[{"label":"Lau J. et al., Discovery of the once-weekly GLP-1 analogue semaglutide.","url":"https://pubmed.ncbi.nlm.nih.gov/26308095/","pmid":"26308095","doi":"10.1021/acs.jmedchem.5b00726"},{"label":"Knudsen L.B., Lau J., The discovery and development of liraglutide and semaglutide.","url":"https://pubmed.ncbi.nlm.nih.gov/31031702/","pmid":"31031702"}]},{"slug":"tirzepatide","name":"Tirzepatide","aliases":["LY3298176","GIP/GLP-1 dual agonist"],"cas":"2023788-19-2","molecular_formula":"C225H348N48O68","monoisotopic_mass":null,"sequence":"YX{Aib}EGTFTSDYSIX{Aib}LDKIAQK(γGlu-γGlu-C20-diacid)AFVQWLIAGGPSSGAPPPS","url":"https://certiklabs.com/peptides/tirzepatide","summary":"Tirzepatide is a 39-residue synthetic peptide that activates both the GIP and GLP-1 receptors. Two α-aminoisobutyric acid (Aib) residues stabilize the backbone against DPP-4 cleavage, and Lys20 carries a γGlu-γGlu spacer linked to a C20 fatty diacid for albumin binding. CertikLabs verifies identity, purity, lipid-conjugation site, and content.","mechanism_summary":"Co-activates GIP and GLP-1 receptors. The pharmacology is detailed in the discovery paper (Coskun et al., 2018) and subsequent reviews; CertikLabs reports only what is needed to verify the chemistry of a supplied sample.","common_impurities":["Deletion or truncation sequences across the long backbone","Aib-position diastereomers","Mis-acylated lipid-linker isomers","Free C20-diacid linker","Oxidized methionine / tryptophan variants","Aggregates and high-molecular-weight species"],"citations":[{"label":"Coskun T. et al., LY3298176, a novel dual GIP and GLP-1 receptor agonist.","url":"https://pubmed.ncbi.nlm.nih.gov/30293770/","pmid":"30293770","doi":"10.1016/j.molmet.2018.09.009"},{"label":"Willard F.S. et al., Tirzepatide: pharmacology of a dual GIP and GLP-1 receptor agonist.","url":"https://pubmed.ncbi.nlm.nih.gov/35551238/","pmid":"35551238"}]},{"slug":"tb-500","name":"TB-500","aliases":["Thymosin β4 (synthetic)","Tβ4","Thymosin beta-4 acetate"],"cas":"77591-33-4","molecular_formula":"C212H350N56O78S","monoisotopic_mass":null,"sequence":"SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES","url":"https://certiklabs.com/peptides/tb-500","summary":"TB-500 is the synthetic version of thymosin β4 (Tβ4), a 43-amino-acid actin-sequestering peptide. It is commonly supplied as the N-terminally acetylated full-length sequence and studied in preclinical models of wound healing, cardiac repair, and angiogenesis. Independent verification matters because the long backbone and Met residue at position 6 create characteristic SPPS and oxidation-derived impurities that a basic identity check will miss.","mechanism_summary":"Thymosin β4 binds monomeric G-actin and regulates the G/F-actin equilibrium. Published preclinical work describes pro-angiogenic, anti-inflammatory, and cell-migration effects mediated via the actin cytoskeleton and downstream Ac-SDKP fragment release. No clinical efficacy or safety claims are made here.","common_impurities":["Deletion sequences across the 43-residue backbone","C-terminal truncations after Lys/Arg-rich middle region","Met(6) oxidation (sulfoxide and sulfone)","Deamidation at Asn/Gln residues","Aspartimide formation at Asp-Lys and Asp-Met segments","Aggregates and dimers (disulfide-independent)","Residual TFA or acetate counter-ion"],"citations":[{"label":"Goldstein A.L. et al., Thymosin β4: a multi-functional regenerative peptide.","url":"https://pubmed.ncbi.nlm.nih.gov/22372513/","pmid":"22372513"},{"label":"Crockford D. et al., Thymosin beta-4: structure, function, and biological properties supporting current and future clinical applications.","url":"https://pubmed.ncbi.nlm.nih.gov/20955195/","pmid":"20955195"}]},{"slug":"ghk-cu","name":"GHK-Cu","aliases":["Copper tripeptide-1","Glycyl-L-histidyl-L-lysine copper(II) complex"],"cas":"89030-95-5","molecular_formula":"C14H22CuN6O4","monoisotopic_mass":null,"sequence":"GHK","url":"https://certiklabs.com/peptides/ghk-cu","summary":"GHK-Cu is a 1:1 complex of the tripeptide Gly-His-Lys (GHK, CAS 49557-75-7) with copper(II). The free peptide GHK is a naturally occurring fragment of human collagen α2(I); when bound to Cu(II) it forms a square-planar chelate that is the active species in most published wound-healing and dermatological literature. CertikLabs verifies both the peptide identity and the stoichiometry of the copper complex.","mechanism_summary":"Published literature describes effects on wound repair, extracellular matrix remodeling, antioxidant activity, and modulation of copper-dependent enzymes. The copper coordination is essential — the apo-peptide GHK has substantially different activity than the GHK-Cu complex.","common_impurities":["Free (uncomplexed) GHK peptide and free copper salts","Off-stoichiometry complexes (2:1 GHK:Cu and 1:2 GHK:Cu species)","Oxidized histidine variants","Truncations (GH, HK dipeptide impurities)","Other trace metal contaminants (Fe, Zn, Ni) competing for the chelation site"],"citations":[{"label":"Pickart L., Margolina A., Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data.","url":"https://pubmed.ncbi.nlm.nih.gov/29462900/","pmid":"29462900","doi":"10.3390/ijms19071987"},{"label":"Pickart L. et al., GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration.","url":"https://pubmed.ncbi.nlm.nih.gov/26236730/","pmid":"26236730"}]},{"slug":"retatrutide","name":"Retatrutide","aliases":["LY3437943","GIP/GLP-1/glucagon triagonist"],"cas":"2381089-83-2","molecular_formula":null,"monoisotopic_mass":null,"sequence":null,"url":"https://certiklabs.com/peptides/retatrutide","summary":"Retatrutide is a 39-residue synthetic peptide that activates the GIP, GLP-1, and glucagon receptors. The backbone contains α-aminoisobutyric acid (Aib) substitutions to resist DPP-4 cleavage, and a lysine in the middle of the sequence carries a γGlu spacer linked to a C20 fatty diacid that drives albumin binding and a long plasma half-life. CertikLabs verifies identity, purity, lipid-conjugation site, and content of supplied material.","mechanism_summary":"Co-activates GIP, GLP-1, and glucagon receptors. Discovery and early clinical pharmacology are described in Coskun et al. (2022) and the Jastreboff et al. Phase 2 obesity trial (NEJM 2023). CertikLabs reports only what is needed to verify the chemistry of a supplied sample.","common_impurities":["Deletion or truncation sequences across the long backbone","Aib-position diastereomers from racemization","Mis-acylated lipid-linker isomers (wrong Lys)","Free C20-diacid linker","Oxidized methionine / tryptophan variants","Aggregates and high-molecular-weight species"],"citations":[{"label":"Coskun T. et al., LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist.","url":"https://pubmed.ncbi.nlm.nih.gov/35921818/","pmid":"35921818","doi":"10.1016/j.cmet.2022.07.013"},{"label":"Jastreboff A.M. et al., Triple-hormone-receptor agonist retatrutide for obesity — Phase 2 trial.","url":"https://pubmed.ncbi.nlm.nih.gov/37356073/","pmid":"37356073","doi":"10.1056/NEJMoa2301972"}]},{"slug":"cjc-1295","name":"CJC-1295","aliases":["CJC-1295 with DAC","DAC:GRF","Modified GRF (1-29) with DAC"],"cas":"863288-34-0","molecular_formula":"C165H269N47O46","monoisotopic_mass":null,"sequence":"YX{D-Ala}DAIFTX{Q-NH2}SYRKVLAQLSARKLLQDIMSRX{Lys-MPA}","url":"https://certiklabs.com/peptides/cjc-1295","summary":"CJC-1295 (with DAC) is a synthetic 30-residue analog of growth-hormone-releasing hormone (GHRH 1-29) with four amino-acid substitutions (D-Ala2, Gln8, Ala15, Leu27) for protease resistance and a C-terminal lysine bearing a maleimidopropionic acid (MPA) Drug Affinity Complex linker. The maleimide forms a covalent bond with the free cysteine of circulating serum albumin, extending the plasma half-life dramatically compared with the bare GHRH peptide.","mechanism_summary":"Agonist at the GHRH receptor on pituitary somatotrophs. Stimulates pulsatile growth-hormone release. The DAC linker is the defining feature; without it the analog is conventionally called Modified GRF(1-29) or CJC-1295 without DAC and has a much shorter half-life.","common_impurities":["Hydrolyzed maleimide (succinamic acid) — non-reactive DAC variant","Free unmodified Modified GRF(1-29) lacking the DAC linker","DAC-linker isomers attached to the wrong lysine","Asp/Asn deamidation and aspartimide products","Truncations and deletion sequences across the 30-mer backbone","Aggregates and dimers (maleimide-mediated cross-links)"],"citations":[{"label":"Teichman S.L. et al., Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults.","url":"https://pubmed.ncbi.nlm.nih.gov/16352683/","pmid":"16352683","doi":"10.1210/jc.2005-1536"},{"label":"Jetté L. et al., Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor and stimulate GH release.","url":"https://pubmed.ncbi.nlm.nih.gov/15919748/","pmid":"15919748"}]},{"slug":"ipamorelin","name":"Ipamorelin","aliases":["NNC 26-0161"],"cas":"170851-70-4","molecular_formula":"C38H49N9O5","monoisotopic_mass":711.3856,"sequence":"X{Aib}-His-D-2-Nal-D-Phe-Lys-NH2","url":"https://certiklabs.com/peptides/ipamorelin","summary":"Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 (C-terminal amide). It contains two non-natural residues — α-aminoisobutyric acid at the N-terminus and 3-(2-naphthyl)-D-alanine at position 3 — and a D-Phe at position 4, which together confer selectivity for the ghrelin receptor and protease resistance.","mechanism_summary":"Selective agonist of the growth-hormone secretagogue receptor (GHS-R1a, the ghrelin receptor). In published animal and early-phase human work it stimulates pituitary growth-hormone release without the parallel rise in ACTH, cortisol, or prolactin seen with non-selective secretagogues such as GHRP-6.","common_impurities":["Diastereomers from racemization of D-2-Nal or D-Phe","Truncations and deletion sequences","Oxidation at the imidazole of His","Free acid (loss of the C-terminal amide)","Residual TFA counter-ion from cleavage"],"citations":[{"label":"Raun K. et al., Ipamorelin, the first selective growth hormone secretagogue.","url":"https://pubmed.ncbi.nlm.nih.gov/9849822/","pmid":"9849822"},{"label":"Gobburu J.V. et al., Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone-releasing peptide.","url":"https://pubmed.ncbi.nlm.nih.gov/10460063/","pmid":"10460063"}]},{"slug":"pt-141","name":"PT-141 (Bremelanotide)","aliases":["Bremelanotide","PT-141"],"cas":"189691-06-3","molecular_formula":"C50H68N14O10","monoisotopic_mass":1024.5243,"sequence":"Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH","url":"https://certiklabs.com/peptides/pt-141","summary":"PT-141 (bremelanotide) is a synthetic cyclic heptapeptide derived from α-melanocyte-stimulating hormone (α-MSH). It is N-terminally acetylated and contains a lactam bridge between Asp and Lys side chains that locks the active core into a constrained β-turn. The molecule is the active pharmaceutical ingredient in an FDA-approved product for a specific clinical indication; CertikLabs verifies the chemistry of supplied material and does not publish clinical guidance.","mechanism_summary":"Non-selective agonist of the melanocortin receptors, with activity at MC1R, MC3R, MC4R, and MC5R. Published pharmacology centers on MC4R activation in the central nervous system. CertikLabs does not publish dosing or clinical recommendations.","common_impurities":["Linear (non-cyclized) precursor lacking the Asp-Lys lactam bridge","D-Phe / L-Phe diastereomer from racemization","Cyclization isomers (wrong-direction lactam, head-to-tail vs side-chain)","Oxidized tryptophan variants (kynurenine, hydroxytryptophan)","Deamidation at His or Asp","Residual TFA or acetate counter-ion"],"citations":[{"label":"Molinoff P.B. et al., PT-141: a melanocortin agonist for the treatment of sexual dysfunction.","url":"https://pubmed.ncbi.nlm.nih.gov/14684464/","pmid":"14684464"},{"label":"Diamond L.E. et al., Co-administration of bremelanotide with sildenafil in patients with erectile dysfunction.","url":"https://pubmed.ncbi.nlm.nih.gov/16422852/","pmid":"16422852"}]},{"slug":"sermorelin","name":"Sermorelin","aliases":["GHRH(1-29)-NH2","GRF(1-29)","Geref"],"cas":"86168-78-7","molecular_formula":"C149H246N44O42S","monoisotopic_mass":null,"sequence":"YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2","url":"https://certiklabs.com/peptides/sermorelin","summary":"Sermorelin is the synthetic 29-residue N-terminal fragment of human growth-hormone-releasing hormone (GHRH), supplied as the C-terminal amide. The 29-mer retains the full intrinsic GHRH-receptor agonist activity of the 44-residue native hormone. CertikLabs verifies identity, purity, and content; it does not publish dosing or clinical guidance.","mechanism_summary":"Agonist at the GHRH receptor on pituitary somatotrophs, stimulating pulsatile growth-hormone release. Pharmacology is well established in the published GHRH literature.","common_impurities":["Truncations at the C-terminus (loss of Arg-NH2, des-Arg29 variants)","Met(27) oxidation (sulfoxide and sulfone)","Deamidation of Asn8 and Gln residues","Aspartimide formation at Asp-Met and Asp-Lys segments","Free acid (loss of the C-terminal amide)","Residual TFA or acetate counter-ion"],"citations":[{"label":"Thorner M.O. et al., Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents.","url":"https://pubmed.ncbi.nlm.nih.gov/7768338/","pmid":"7768338"},{"label":"Prakash A., Goa K.L., Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.","url":"https://pubmed.ncbi.nlm.nih.gov/10937325/","pmid":"10937325"}]}]}}